Abstract
The recent adoption of drugs that inhibit the actions of VEGF has dramatically changed ophthalmology. The intravitreal injection of potent anti-VEGF medications, particularly bevacizumab and ranibizumab, has become standard-of-care for the treatment of the most common blinding diseases – exudative age-related macular degeneration and diabetic macular edema. The introduction of aflibercept, a high binding affinity fusion protein, gives physicians another valuable tool for the treatment of these conditions. The VIEW 1 and 2 trials showed that monthly and bimonthly aflibercept was equivalent to monthly ranibizumab for the treatment of age-related macular degeneration, and the COPERNICUS and GALILEO trials showed that aflibercept was far superior to sham injections for the treatment of macular edema due to central retinal vein occlusions. Ongoing trials are investigating the efficacy of aflibercept for the treatment of edema due to diabetic retinopathy, branch retinal vein occlusions and myopic choroidal neov...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
